The impact of stepwise withdrawal of inhaled corticosteroids on exacerbations in COPD patients receiving dual bronchodilation: WISDOM study
H Magnussen, P Chanez, R Dahl, M Decramer, B Disse, H Finnigan, AM Kirsten, R Rodriguez-Roisin, K Tetzlaff, L Towse, H Watz, E Wouters, P Calverley · Pneumologie · 2015 · Heft 02
Bibliografische Angaben
Zusammenfassung
Background: Although guidance recommends ICS for prevention of recurrent COPD exacerbations, there is still uncertainty about the benefits of ICS. Objective: To evaluate the effects of stepwise withdrawal of ICS in patients (pts) with GOLD 3 – 4 COPD and a history of exacerbation who are treated with LAMA+LABA. Methods: WISDOM (NCT00975195) was a 12-month, double-blind, parallel-group, active-controlled study in which all pts received triple therapy (tiotropium 18 µg QD, salmeterol 50 µg BID and fluticasone 500 µg BID) for a 6-week run-in period. Pts were randomised 1:1 to continue triple therapy or stepwise wit…
